Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.33 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.32 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3088634 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL29608 | 0.99 | KDM4E (0.34) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL9308713 | 0.99 | KDM4E (0.34) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL9309462 | 0.99 | KDM4E (0.34) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL195167 | 0.96 | KDM4E (0.33) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL3083871 | 0.88 | ADRB3 (0.35) | SMN1; SMN2CYP3A4CYP2D6KDM4EADRB3 | |
| Hydrochloric Acid SCHEMBL29377696 | 0.88 | ADRB3 (0.35) | SMN1; SMN2CYP3A4CYP2D6KDM4EADRB3 | |
| Hydrochloric Acid SCHEMBL3083869 | 0.88 | ADRB3 (0.35) | SMN1; SMN2CYP3A4CYP2D6KDM4EADRB3 | |
| SCHEMBL15562859 | 0.86 | ADRB3 (0.35) | CYP3A4CYP1A2CYP2D6ADRB3CA12 | |
| SCHEMBL9308678 | 0.86 | ADRB3 (0.35) | CYP3A4CYP1A2CYP2D6ADRB3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | claimed |
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1514542-B1 | Medicinal composition comprising Tacrine or Donepezil for improving brain function. | TOYAMA CHEMICAL CO LTD (JP) | 2012-02-22 | — | — | EP | disclosed |
| EP-2389937-A1 | Medicinal composition for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-8038956-B2 | Catalyzed soot filter manufacture and systems | BASF CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-RE42327-E1 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834053-B2 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-1186594-B1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20050250843-A1 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040014777-A1 | Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1325744-A1 | REMEDIES FOR RETINAL NERVE DISEASES CONTAINING 1,2-ETHANEDIOL DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349976-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | ADRB3 58/4885CA2 4471/4885MMP13 2955/4885 |
| US-20050250843-A1 | Medicinal compositions improving brain function and method for improving brain function | CHRM2, ACHE, CHAT | ADRB3 55/4885CA2 326/4885MMP13 521/4885 |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | ADRB3 1450/4885CA2 1849/4885MMP13 2627/4885 |
| US-20090082388-A1 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | CHAT, ACHE, SLC18A3 | ADRB3 58/4885CA2 4471/4885MMP13 2955/4885 |
| US-20040014777-A1 | Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof | ALDH1A2, NR2E3, GRIA3 | ADRB3 221/4885CA2 1292/4885MMP13 1843/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | ADRB3 1450/4885CA2 1849/4885MMP13 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.